Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5824906 | Clinical Therapeutics | 2015 | 12 Pages |
Abstract
Liraglutide 1.2Â mg and 1.8Â mg were associated with the lowest cost of control values, driven by the high proportion of patients achieving the composite end point, which offset the higher medication costs. A relatively low cost of control value was achieved for glimepiride, driven by low acquisition costs, despite relatively few patients achieving the composite end point.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Rasmus MSc, Uffe MSc, Barnaby MSc, William J. PhD,